In this Q&A session, we get to know William Hunter, Director of Business Development and Global Key Accounts at BioAgilytix Europe, as he discusses why he moved to Germany for his role and what he sees coming for BioAgilytix in the industry.
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). CAR-T cells have demonstrated clinical efficacy in hematologic malignancies and targeting solid tumors. However, CAR-T therapy also can elicit cytokine release syndrome (CRS) cytotoxicity. This unwanted release of cytokines has also been seen following the infusion of therapeutic monoclonal antibodies (mAbs), systemic interleukin-2 (IL-2), and the bispecific CD19-CD3 T-cell engaging antibody blinatumomab.
In this Q&A session, we get to know Florian Sieglitz, Principal Investigator / Bioanalytical Project Manager (BPM) at BioAgilytix Europe, as he discusses his experiences working in drug development and how his role with BioAgilytix Europe is growing along with the company.
Scientists from BioAgilytix recently attended the 12th WRIB in Philadelphia, PA. Meeting new contacts in the industry and taking part in discussions concerning the most innovative topics in bioanalysis, biomarkers, and immunogenicity was a genuinely valuable and enjoyable experience. We recap the topics that our team found to be most interesting at WRIB this year.
This year, we are proud to be celebrating our 10 year anniversary and a decade of doing large molecule bioanalysis differently. To all of our employees, clients, colleagues, and friends: thank you for helping us make this a remarkable decade for BioAgilytix.
Many immuno-oncology therapies are seeing success and showing promise for the future, including CAR-T cells, tumor-infiltrating lymphocytes (TILs), checkpoint inhibitors, and natural killer cell therapies. However, there are still many challenges (e.g. cytokine release syndrome in CAR-T therapies) that we as scientists must deal with when working in this new arena of drug development.
Platforms
Services